IP Library Granted Patent US 10,507,265
Granted Patent B2
US 10,507,265 · App. 15/596,237 · Granted Dec 17, 2019

Cancellous bone product including viable osteogenic cells

Inventors: Michelle LeRoux Williams (Laurel, MD); Charles Randal Mills (Finksburg, MD); Rodney Monroy (Aberdeen, MD)
Assignee: NuVasive, Inc.
A61L27/3608A61L27/365A61L27/3683A61L27/3687A61F2/28A61F2310/00359A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,265
App. No.
15/596,237
Granted
Dec 17, 2019
Kind
B2
Abstract

A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation.

Claims (24)

1. A bone product, comprising:

cancellous bone matrix essentially free of hematopoietic cells, said cancellous bone matrix including native, viable osteogenic cells;

demineralized bone matrix; and

a cryopreservative;

wherein the cancellous bone matrix has been treated to partially digest the cancellous bone matrix and enhance availability of the native, viable osteogenic cells for carrying out their osteogenic function.

2. The bone product of claim 1 , wherein the cancellous bone matrix and the cryopreservative are combined in a sealed container.

3. The bone product of claim 1 , wherein the bone product is frozen.

4. The bone product of claim 3 , wherein upon thawing of the bone product, at least 70% of the native, viable osteogenic cells are viable.

5. The bone product of claim 4 , wherein the bone product when frozen are stored in the cryopreservative at −80 degrees Celsius±5 Celsius for a period of seventeen days.

6. The bone product of claim 1 , wherein the bone product has been treated with at least one of an antibiotic or at least one of an antimycotic.

7. The bone product of claim 1 , wherein the bone product comprises cancellous bone chips.

8. The bone product of claim 1 , wherein the bone product comprises milled cancellous bone.

9. The bone product of claim 1 is an allograft bone product.

10. A bone product, comprising:

treated cancellous bone essentially free of hematopoeitic cells, said cancellous bone matrix including native, viable osteogenic cells;

untreated bone; and

a cryopreservative;

wherein the cancellous bone matrix has been treated with a loosening agent to enhance availability of the native, viable osteogenic cells for carrying out their osteogenic function.

11. The bone product of claim 10 , wherein the untreated bone comprises at least one of allograft bone chips, fragments, and powder.

12. The bone of claim 10 , wherein the treated cancellous bone matrix, untreated bone and the cryopreservative are combined in a sealed container.

13. The bone product of claim 10 , wherein the loosening agent is a collagenase.

14. The bone product of claim 10 , wherein the loosening agent is a digestive enzyme.

15. The bone product of claim 10 , wherein the treated cancellous bone matrix comprises cancellous bone chips.

16. The bone product of claim 10 , wherein the treated cancellous bone matrix comprises milled cancellous bone.

Assignments (3)
SECURITY INTEREST Recorded Feb 28, 2020
From: NUVASIVE, INC.; NUVASIVE CLINICAL SERVICES MONITORING, INC.; NUVASIVE CLINICAL SERVICES, INC.; NUVASIVE SPECIALIZED ORTHOPEDICS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 052918/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2018
From: WILLIAMS, MICHELLE LEROUX; MILLS, CHARLES RANDAL; MONROY, RODNEY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 046197/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2018
From: OSIRIS THERAPEUTICS, INC.
To: NUVASIVE, INC.
Reel/Frame 046197/0370 →
Continuity (5)
Continuation 13915569 · Jun 11, 2013
Continuation 11799606 · May 2, 2007
Provisional Application 60831723 · Jul 18, 2006
Provisional Application 60798474 · May 8, 2006
Related Publication 20170246349A1 · Aug 31, 2017